Datapoint: BMS Settles HIV Antitrust Suit
Bristol Myers Squibb could pay up to $11 million to settle a lawsuit brought by HIV activists, which claimed the company used anticompetitive practices to block generic competition to its HIV drugs, including Evotaz. Evotaz is a cocktail therapy, made in partnership between BMS and Gilead Sciences. Gilead and Johnson & Johnson are set to move forward with a trial, beginning sometime in 2023. Under the pharmacy benefit, 92% of all insured lives have covered or better access to Evotaz as an HIV antiviral. 47.3% of lives have preferred access to Evotaz, without utilization management restrictions.
SOURCE: MMIT Analytics, as of 4/15/22
© 2025 MMIT